2025
Introduction
- What information is available on IV fosfomycin for the treatment of complicated urinary tract infections?
- Is there evidence to support the use of piperacillin-tazobactam for the treatment of necrotizing pancreatitis?
- Overview of the 2025 Hypertension Guidelines
- What is the role of azelastine nasal spray in the management of COVID-19?
- What is the latest information on subcutaneous semaglutide for MASLD/MASH?
- What do national and international health organizations say about the link between Tylenol (acetaminophen) use and autism?
- What is the available literature on the risk of inhaled corticosteroid (ICS)-induced adrenal insufficiency in preterm infants with bronchopulmonary dysplasia (BPD)?
- What data is available regarding partner treatment to prevent recurrence of bacterial vaginosis?
- What new drugs are available for the management of hereditary angioedema?
- What evidence and recommendations support the use of clesrovimab for prevention of RSV?
- What information is available about the use of suzetrigine, an oral sodium channel blocker, for moderate to severe acute pain in adults?
- What is the role of daptomycin for vancomycin-resistant Enterococcus (VRE) prophylaxis in liver transplant recipients?
- What conservation strategies are available if medication administration filters are on limited supply?
- Update: Can a simplified 2-bag acetylcysteine approach improve tolerability in acetaminophen overdoses?
- What Are the Safety Concerns Regarding Compounded GLP-1 Receptor Agonists?
- What are the most up to date guideline recommendations for the treatment of Lyme disease?
- What evidence evaluates rectal administration of P2Y12 inhibitors?
- Update: What is the Role of Tranexamic Acid in Patients with Acute Gastrointestinal Bleeding?
- What are the expanded recommendations for pneumococcal conjugate vaccine use in adults?
- What information is available on the new drug gepotidacin for treatment of uncomplicated urinary tract infections?
- Update: What data support the use of andexanet alfa (ANDEXXA) for the reversal of factor Xa inhibitors?
- What data are available on apixaban for treatment of left ventricular thrombus?
- Do long-acting injectable antipsychotics have a higher risk of QTc prolongation than immediate-acting antipsychotics?
- What evidence supports the use of colchicine for the secondary prevention of cardiovascular events?
- What literature supports a maximum dose of unfractionated heparin in patients with obesity?
- How should metronidazole be used for chronic wound odor?
- What information is available regarding yellow fever vaccine administration in patients with egg allergy?
- What information is available on the use of omalizumab for IgE-mediated food allergy?
- What evidence evaluates the use of Paxlovid™ (nirmatrelvir/ritonavir) in severe renal impairment?
- What guidelines are available about ketamine use in the management of complex regional pain syndrome?
- What are the recommendations to identify and manage Shoulder Injury Related to Vaccine Administration (SIRVA)?
- Is there evidence to support initiation of remdesivir after 7 days in hospitalized patients with severe COVID-19?
- Is there literature, specifically guidelines, available on how to medically manage adverse reactions associated with intravenous iron?
- Is there evidence supporting the use of remdesivir for longer than 10 days in the treatment of COVID-19?
- What are the latest guideline recommendations for the treatment of Helicobacter pylori infection in the U.S.?
- What information is available regarding the new antipsychotic xanomeline/trospium?